Stockreport

Trevi Therapeutics (TRVI) Valuation Check After FDA End Of Phase 2 Update And Renewed Analyst Optimism [Yahoo! Finance]

Trevi Therapeutics, Inc.  (TRVI) 
PDF See our latest analysis for Trevi Therapeutics. Those clinical updates and recent broker commentary come after a mixed price patch, with the share price at US$11.18, [Read more]